Chinese clinical stage biotechnology company Shanghai Yingli Pharmaceutical Co Ltd (Yingli Pharma) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) to initiate a global registration Phase 3 study of linperlisib versus physicians' choice of standard of care, for the treatment of relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
This approval follows a successful Type B End-of-Phase 2 meeting, during which the company discussed the overall development program and regulatory path.
Yingli Pharma expects the Phase 3 study to commence during the second quarter of 2025.
Linperlisib is a potent oral small molecule inhibitor of the delta isoform of PI3 kinase (PI3K delta) developed by Yingli Pharma.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval